title: AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.
abstract: OBJECTIVE
  Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non- Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT.
  
  
  METHODS
  The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone.
  
  
  RESULTS
  Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 x 10(9) lymphocytes/kg vs. 0.288 x 10(9) lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02).
  
  
  CONCLUSIONS
  Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.
authors.affiliation: Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
authors.forename: Shernan G
authors.initials: SG
authors.lastname: Holtan
authors.forename: Luis F
authors.initials: LF
authors.lastname: Porrata
authors.forename: Ivana N M
authors.initials: IN
authors.lastname: Micallef
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Padley
authors.forename: David J
authors.initials: DJ
authors.lastname: Inwards
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Ansell
authors.forename: Patrick B
authors.initials: PB
authors.lastname: Johnston
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Gastineau
authors.forename: Svetomir N
authors.initials: SN
authors.lastname: Markovic
mesh_terms: D000328:Adult; D000368:Aged; D001596:Benzylamines; D000080027:Cyclams; D018572:Disease-Free Survival; D005260:Female; D006571:Heterocyclic Compounds / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000187:drug effects*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D033581:Stem Cell Transplantation / Q000379:methods*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor